View all Medical Crossfire CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.


PER Pulse™ Recaps highlight key elements of the Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future Direction online CME activity.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Clovis Oncology Inc., Foundation Medicine Inc., and Tesaro Inc.

Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future Direction

Release Date: January 30, 2017
Expiration Date: January 30, 2018
Media: Internet - based


Activity Overview

This edition of Medical Crossfire®, filmed in conjunction with the 34th Annual CFS™ Chemotherapy Foundation Symposium®, has been designed to provide a dynamic discussion of the expanding role of poly ADP-ribose polymerase (PARP) inhibitors in the care of patients with ovarian cancer. With two PARP inhibitors already approved for ovarian cancer (in patients with BRCA-mutated disease) by the Food and Drug Administration and others in phase III testing in various indications, the time is now for clinicians to get up-to-date on the rationale for the use of PARP inhibitors in this lethal disease, as well as the established and emerging clinical data supporting their use.

Our activity chair, Maurie Markman, MD, and our expert faculty will each discuss key topics related to PARP inhibitors in ovarian cancer, including their rationale, resistance mechanisms to PARP inhibition, their use in different treatment strategies, and the role of genetic testing to identify those patients to be treated with these agents. An engaging panel discussion will be led by Dr. Markman.

CME/CE Activity Table of Contents

  • Introduction
    Maurie Markman, MD
  • Module I: Rationale for Use of PARP Inhibitors in Ovarian Cancer
    Faculty Panel
  • Module II: Current Data Using PARP Inhibitors in Ovarian Cancer
    Faculty Panel
  • Module III: Resistance Mechanisms to PARP Inhibition in Ovarian Cancer
    Faculty Panel
  • Module IV: Genetic Testing and Biomarkers
    Faculty Panel
  • Module V: Settings and Sequencing of PARP Inhibitors
    Faculty Panel
  • Key Takeaways
    Faculty Panel
  • Posttest


Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, "educational content/video files" will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward all attendees of the 34th Annual CFS™ Chemotherapy Foundation Symposium®, including physicians, nurse practitioners, nurses, and physician assistants with an interest in treating patients with ovarian cancer. Pharmacists, researchers, and other health care providers interested in the treatment of ovarian cancer are also invited to participate.

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Describe the rationale for the application of PARP inhibitors in ovarian cancer
  • Outline the resistance mechanisms to PARP inhibitors in ovarian cancer
  • Discuss the evolving treatment strategies for PARP inhibition in the treatment of ovarian cancer, including the role in monotherapy, combination therapy, and maintenance therapy
  • Assess the role of genetic testing and biomarkers for the identification of patients with ovarian cancer to be treated with PARP inhibition, including those with BRCA-mutated disease

Faculty, Staff, and Planners' Disclosures


Maurie Markman, MD
Medical Oncologist
President, Medicine and Science
Cancer Treatment Centers of America
Philadelphia, PA

Disclosure: Consultant: Amgen, Celgene, Pfizer, CritiTech; Speakers Bureau: Genentech, AstraZeneca


Michael J. Birrer, MD, PhD
Professor, Harvard Medical School
Director, Gynecologic Medical Oncology
Massachusetts General Hospital Cancer Center
Boston, MA

Disclosure: Advisory Board Member: Roche Laboratories, Inc., Sanofi, Acceleron Pharmaceuticals, Inc., Merrimack Pharmaceuticals, Inc., Oxigene, Threshold Pharmaceuticals

Michael A. Bookman, MD
Director, Gynecologic Oncology Research
US Oncology Research
Arizona Oncology
Tucson, AZ

Disclosure:Ad Hoc Advisory Boards, Gynecologic Oncology Research with Investigational Agents: AbbVie, AstraZeneca, Clovis Oncology, Endocyte, ImmunoGen, Tesaro, Genentech/Roche, Cerulean Pharma; Protocol Steering Committee: AbbVie, Mateon Therapeutics, Genentech/Roche; Independent Data Monitoring Committee: ImmunoGen.

Mark E. Robson, MD
Professor of Medicine
Clinic Director, Clinical Genetics Service
Memorial Sloan Kettering Cancer Center
New York, NY
Boston, MA

Disclosure: Consultant: Pfizer, GE Health; Other: Institutional Research Support: AbbVie, AstraZeneca, Biomarin

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive, Suite 110
Cranbury, NJ 08512
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705


Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By